NX-0451
Solid Tumors
Key Facts
About Nurix Therapeutics
Nurix Therapeutics is a leader in the targeted protein degradation (TPD) space, with a mission to develop breakthrough therapies for cancer and autoimmune diseases by harnessing the body's natural protein disposal systems. The company's core achievement is the development of its integrated DELigase™ discovery platform, which combines DNA-encoded libraries (DEL), artificial intelligence (AI), and deep E3 ligase expertise to rapidly generate novel degrader candidates. Its strategy involves advancing a multi-modal pipeline of oral degraders and antibody-conjugated degraders (DACs), with its lead asset, bexobrutideg (NX-5948), in Phase 2 trials for hematologic cancers. Nurix aims to establish degrader-based medicines as a cornerstone of future patient care through both internal development and strategic partnerships.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |
| Undisclosed Whole Cell Vaccine Program(s) | Neuvogen | Pre-clinical |
| SY-5609 | Syros Pharmaceuticals | Phase 1/2 |
| Not Specified (TCR Therapy) | T-Cure Bioscience | Phase 1 |
| B7-H3 Program | Ocean Biomedical | Discovery |